CN110997671A - 作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物 - Google Patents

作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物 Download PDF

Info

Publication number
CN110997671A
CN110997671A CN201880050882.9A CN201880050882A CN110997671A CN 110997671 A CN110997671 A CN 110997671A CN 201880050882 A CN201880050882 A CN 201880050882A CN 110997671 A CN110997671 A CN 110997671A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
methoxy
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050882.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·俞
M·余
M·赞卡内尔拉
Z·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of CN110997671A publication Critical patent/CN110997671A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201880050882.9A 2017-06-09 2018-06-07 作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物 Pending CN110997671A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517410P 2017-06-09 2017-06-09
US62/517,410 2017-06-09
PCT/US2018/036521 WO2018226998A1 (en) 2017-06-09 2018-06-07 Azaindole compounds as histone methyltransferase inhibitors

Publications (1)

Publication Number Publication Date
CN110997671A true CN110997671A (zh) 2020-04-10

Family

ID=62779058

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050882.9A Pending CN110997671A (zh) 2017-06-09 2018-06-07 作为组蛋白甲基转移酶抑制剂的氮杂吲哚化合物

Country Status (11)

Country Link
US (2) US11111243B2 (enExample)
EP (1) EP3634962B1 (enExample)
JP (1) JP7225125B2 (enExample)
CN (1) CN110997671A (enExample)
AR (1) AR112192A1 (enExample)
BR (1) BR112019025770A2 (enExample)
ES (1) ES2949402T3 (enExample)
IL (1) IL271066A (enExample)
MX (1) MX2019014759A (enExample)
TW (1) TW201920165A (enExample)
WO (1) WO2018226998A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114394971A (zh) * 2022-01-24 2022-04-26 云南大学 一种吲哚咔唑类化合物的制备方法
CN116848122A (zh) * 2021-02-05 2023-10-03 赛诺哈勃药业（成都）有限公司 一种纤溶酶抑制剂、其制备方法及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099068A1 (en) * 2000-03-15 2002-07-25 Olaf Ritzeler Substituted beta carbolines
WO2008055233A1 (en) * 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
US20110142796A1 (en) * 2007-12-19 2011-06-16 Amgen Inc Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors
US20110275762A1 (en) * 2008-11-10 2011-11-10 University Of Basel Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
US20120208819A1 (en) * 2009-10-06 2012-08-16 Joseph Arndt Heterocyclic compounds useful as pdk1 inhibitors
US20120244110A1 (en) * 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US20130116273A1 (en) * 2010-06-25 2013-05-09 Universite Libre De Bruxelles Beta carboline derivatives useful in the treatment of proliferative disorders
US20130231360A1 (en) * 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
RU2532135C2 (ru) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Производные иминопиридина и их применение в качестве микробиоцидов
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
PL2364983T3 (pl) 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
TW201236880A (en) 2011-03-11 2012-09-16 Primax Electronics Ltd Sheet feeding apparatus
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US9284272B2 (en) 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
US10407423B2 (en) 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099068A1 (en) * 2000-03-15 2002-07-25 Olaf Ritzeler Substituted beta carbolines
WO2008055233A1 (en) * 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
US20110142796A1 (en) * 2007-12-19 2011-06-16 Amgen Inc Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors
US20110275762A1 (en) * 2008-11-10 2011-11-10 University Of Basel Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes
US20120208819A1 (en) * 2009-10-06 2012-08-16 Joseph Arndt Heterocyclic compounds useful as pdk1 inhibitors
US20130231360A1 (en) * 2010-04-22 2013-09-05 The Brigham And Women S Hospital, Inc. Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases
US20130116273A1 (en) * 2010-06-25 2013-05-09 Universite Libre De Bruxelles Beta carboline derivatives useful in the treatment of proliferative disorders
US20120244110A1 (en) * 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116848122A (zh) * 2021-02-05 2023-10-03 赛诺哈勃药业（成都）有限公司 一种纤溶酶抑制剂、其制备方法及应用
CN114394971A (zh) * 2022-01-24 2022-04-26 云南大学 一种吲哚咔唑类化合物的制备方法

Also Published As

Publication number Publication date
AR112192A1 (es) 2019-10-02
JP2020523315A (ja) 2020-08-06
JP7225125B2 (ja) 2023-02-20
IL271066A (en) 2020-01-30
EP3634962A1 (en) 2020-04-15
EP3634962B1 (en) 2023-05-24
TW201920165A (zh) 2019-06-01
WO2018226998A1 (en) 2018-12-13
US20180354947A1 (en) 2018-12-13
ES2949402T3 (es) 2023-09-28
US20210371417A1 (en) 2021-12-02
MX2019014759A (es) 2020-02-12
US11111243B2 (en) 2021-09-07
BR112019025770A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
US11046699B2 (en) Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
TWI826416B (zh) 趨化介素受體調節劑及其用途
US10246462B2 (en) Chemokine receptor modulators and uses thereof
TWI817929B (zh) 趨化介素受體調節劑及其用途
US10913727B2 (en) Modulators of the integrated stress pathway
IL262722A (en) Compounds from combined pressure response modulators, preparations containing them and their uses
US10829452B2 (en) Histone methyltransferase inhibitors
CN118359610A (zh) Menin-mll相互作用的抑制剂
US10722514B2 (en) Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
US11661410B2 (en) Tricyclic compounds as histone methyltransferase inhibitors
WO2020068600A1 (en) Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
JP2019511472A (ja) ヒストンメチルトランスフェラーゼ阻害剤
US20220177488A1 (en) Sumo inhibitor compounds and uses thereof
US20210371417A1 (en) Azaindole compounds as histone methyltransferase inhibitors
TW202406902A (zh) 趨化介素受體調節劑及其用途
OA19439A (en) Azaindole compounds as histone methyltranferase inhibitors.
OA19495A (en) Tricyclic compounds as Histone Methyltransferase inhibitors.
BR112019001732B1 (pt) Moduladores de receptor de quimiocina e usos dos mesmos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410

WD01 Invention patent application deemed withdrawn after publication